141762-27-8Relevant articles and documents
Evaluation of 18F-labeled exendin(9-39) derivatives targeting glucagon-like peptide-1 receptor for pancreatic β-cell imaging
Kimura, Hiroyuki,Ogawa, Yu,Fujimoto, Hiroyuki,Mukai, Eri,Kawashima, Hidekazu,Arimitsu, Kenji,Toyoda, Kentaro,Fujita, Naotaka,Yagi, Yusuke,Hamamatsu, Keita,Murakami, Takaaki,Murakami, Atsushi,Ono, Masahiro,Nakamoto, Yuji,Togashi, Kaori,Inagaki, Nobuya,Saji, Hideo
, p. 463 - 469 (2018)
β-cell mass (BCM) is known to be decreased in subjects with type-2 diabetes (T2D). Quantitative analysis for BCM would be useful for understanding how T2D progresses and how BCM affects treatment efficacy and for earlier diagnosis of T2D and development of new therapeutic strategies. However, a noninvasive method to measure BCM has not yet been developed. We developed four 18F-labeled exendin(9-39) derivatives for β-cell imaging by PET: [18F]FB9-Ex(9-39), [18F]FB12-Ex(9-39), [18F]FB27-Ex(9-39), and [18F]FB40-Ex(9-39). Affinity to the glucagon-like peptide-1 receptor (GLP-1R) was evaluated with dispersed islet cells of ddY mice. Uptake of exendin(9-39) derivatives in the pancreas as well as in other organs was evaluated by a biodistribution study. Small-animal PET study was performed after injecting [18F]FB40-Ex(9-39). FB40-Ex(9-39) showed moderate affinity to the GLP-1R. Among all of the derivatives, [18F]FB40-Ex(9-39) resulted in the highest uptake of radioactivity in the pancreas 30 min after injection. Moreover, it showed significantly less radioactivity accumulated in the liver and kidney, resulting in an overall increase in the pancreas-to-organ ratio. In the PET imaging study, pancreas was visualized at 30 min after injection of [18F]FB40-Ex(9-39). [18F]FB40-Ex(9-39) met the basic requirements for an imaging probe for GLP-1R in pancreatic β-cells. Further enhancement of pancreatic uptake and specific binding to GLP-1R will lead to a clear visualization of pancreatic β-cells.
An improved synthesis of n-(4-[18 f]fluorobenzoyl)-interleukin-2 for the preclinical pet imaging of tumour-infiltrating t-cells in ct26 and mc38 colon cancer models
Cheng, Peter,Goggi, Julian L.,Hartimath, Siddesh V.,Jiang, Lingfan,Khanapur, Shivashankar,Narayanaswamy, Pradeep,Ramasamy, Boominathan,Robins, Edward George,Yong, Fui Fong
, (2021/06/16)
Positron emission tomography (PET) imaging of activated T-cells with N-(4-[18 F]fluorobenzoyl)-interleukin-2 ([18 F]FB-IL-2) may be a promising tool for patient management to aid in the assessment of clinical responses to immune ther
NOVEL MOLECULAR ASSEMBLY, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR DRUG DELIVERY SYSTEM USING THE SAME, AND MOLECULAR IMAGING SYSTEM AND DRUG DELIVERY SYSTEM
-
Paragraph 0547-0550, (2019/04/25)
The present invention provides a molecular assembly which is less likely to accumulate in tissue other than cancer tissue, is highly safe for a living body, and can be prepared by a simple and safe method and whose particle size can be easily controlled.
RADIOACTIVE COMPOUND FOR DIAGNOSIS OF MALIGNANT MELANOMA AND USE THEREOF
-
Paragraph 0070, (2019/11/19)
The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging.